An integrated approach for tailored treatment in breast cancer

被引：3

作者：

Awada, A ^{[1
]}

de Castro, G ^{[1
]}

机构：

[1] Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷

关键词：

D O I：

10.1093/annonc/mdi722

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：203 / 208

页数：6

共 49 条

[41] The role of functional and molecular imaging in cancer drug discovery and development [J].

Seddon, BM ;

Workman, P .

BRITISH JOURNAL OF RADIOLOGY, 2003, 76 :S128-S138

[42] Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: Results from the Eastern Cooperative Oncology Group companion study, EST 4189 [J].

Simpson, JF ;

Gray, R ;

Dressler, LG ;

Cobau, CD ;

Falkson, CI ;

Gilchrist, KW ;

Pandya, KJ ;

Page, DL ;

Robert, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) :2059-2069

[43] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[44] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].

Sorlie, T ;

Perou, CM ;

Tibshirani, R ;

Aas, T ;

Geisler, S ;

Johnsen, H ;

Hastie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Thorsen, T ;

Quist, H ;

Matese, JC ;

Brown, PO ;

Botstein, D ;

Lonning, PE ;

Borresen-Dale, AL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874

[45] Docetaxel combined with trastuzumab is an active regimen in HER-2 3+overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial [J].

Tedesco, KL ;

Thor, AD ;

Johnson, DH ;

Shyr, Y ;

Blum, KA ;

Goldstein, LJ ;

Gradishar, WJ ;

Nicholson, BP ;

Merkel, DE ;

Murrey, D ;

Edgerton, S ;

Sledge, GW .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1071-1077

[46] A gene-expression signature as a predictor of survival in breast cancer. [J].

van de Vijver, MJ ;

He, YD ;

van 't Veer, LJ ;

Dai, H ;

Hart, AAM ;

Voskuil, DW ;

Schreiber, GJ ;

Peterse, JL ;

Roberts, C ;

Marton, MJ ;

Parrish, M ;

Atsma, D ;

Witteveen, A ;

Glas, A ;

Delahaye, L ;

van der Velde, T ;

Bartelink, H ;

Rodenhuis, S ;

Rutgers, ET ;

Friend, SH ;

Bernards, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (25) :1999-2009

[47] Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis [J].

Wahl, AF ;

Donaldson, KL ;

Fairchild, C ;

Lee, FYF ;

Foster, SA ;

Demers, GW ;

Galloway, DA .

NATURE MEDICINE, 1996, 2 (01) :72-79

[48] Randomized pharmacokinetic and pharmacodynamic study of docetaxel: Dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol [J].

Yamamoto, N ;

Tamura, T ;

Murakami, H ;

Shimoyama, T ;

Nokihara, H ;

Ueda, Y ;

Sekine, I ;

Kunitoh, H ;

Ohe, Y ;

Kodama, T ;

Shimizu, M ;

Nishio, K ;

Ishizuka, N ;

Saijo, N .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1061-1069

[49] When is a tumor marker ready for prime time?: A case study of c-erbB-2 as a predictive factor in breast cancer [J].

Yamauchi, H ;

Stearns, V ;

Hayes, DF .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2334-2356

← 1 2 3 4 5 →